Update on Breast Cancer Risk Reduction Therapy

被引:0
|
作者
Vogel V.G. [1 ]
机构
[1] Geisinger Health System, 100 North Academy Avenue, M. C. 20-01, Danville, 17822, PA
关键词
Anastrozole; Aromatase inhibitors; Atypical hyperplasia; Chemoprevention; Exemestane; Lobular carcinoma in situ; Mammographic breast density; Raloxifene; Tamoxifen;
D O I
10.1007/s12609-016-0221-8
中图分类号
学科分类号
摘要
In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prolonged immobilization. Chemoprevention with a SERM may be particularly beneficial to women with atypical hyperplasia, a 5-year risk of more than 5 %, in women with increased mammographic density, or in women with lobular carcinoma in situ. Aromatase inhibitor therapy is of value in high-risk postmenopausal women. Toxicity with tamoxifen is minimal in premenopausal women and is less with either raloxifene or an aromatase inhibitor in postmenopausal women. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:175 / 182
页数:7
相关论文
共 50 条
  • [31] Risk factors for breast cancer in women: an update review
    Fakhri, Nada
    Chad, Mohamed Amine
    Lahkim, Mohamed
    Houari, Abdellah
    Dehbi, Hind
    Belmouden, Ahmed
    El Kadmiri, Nadia
    MEDICAL ONCOLOGY, 2022, 39 (12)
  • [32] Breast cancer.: Update in risk factors and prevention
    Soler Lopez, Jordi
    Cases, Ana B.
    Checa, Miguel A.
    del Mar Vernet, Maria
    Carreras, Ramon
    GINECOLOGIA Y OBSTETRICIA CLINICA, 2007, 8 (01): : 29 - 36
  • [33] Risk factors for breast cancer in women: an update review
    Nada Fakhri
    Mohamed Amine Chad
    Mohamed Lahkim
    Abdellah Houari
    Hind Dehbi
    Ahmed Belmouden
    Nadia El Kadmiri
    Medical Oncology, 39
  • [34] Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
    Ozben, Tomris
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2015, 15 (02) : 170 - 178
  • [35] Breast cancer risk prediction: an update to the Rosner–Colditz breast cancer incidence model
    Megan S. Rice
    Shelley S. Tworoger
    Susan E. Hankinson
    Rulla M. Tamimi
    A. Heather Eliassen
    Walter C. Willett
    Graham Colditz
    Bernard Rosner
    Breast Cancer Research and Treatment, 2017, 166 : 227 - 240
  • [36] COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK REDUCTION THERAPY: COMPARING TAMOXIFEN AND RALOXIFENE
    Poon, J. L.
    Hay, J.
    VALUE IN HEALTH, 2010, 13 (03) : A37 - A37
  • [37] Radiation Therapy and Breast Cancer Risk
    Ng, Andrea K.
    Travis, Lois B.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (10): : 1121 - 1128
  • [38] Hormone therapy and risk of breast cancer
    Roman, M.
    Hofvind, S.
    Sakshaug, S.
    Ursin, G.
    Graff-Iversen, S.
    Nezvalova-Henriksen, K.
    Sebuodegard, S.
    Weiderpass, E.
    Vangen, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S77 - S77
  • [39] Insulin Therapy and Breast Cancer Risk
    Pizot, Cecile
    Dragomir, Miruna
    Boyle, Peter
    Autier, Philippe
    DIABETES, 2018, 67
  • [40] Hormone therapy and the risk of breast cancer
    Opatrny, Lucie
    Dell'Aniello, Sophie
    Assouline, Sarit
    Suissa, Samy
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 1015 - 1015